A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Public ClinicalTrials.gov record NCT06323174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
Study identification
- NCT ID
- NCT06323174
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 189 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 19, 2024 (Actual)
- Primary completion
- Oct 1, 2025 (Actual)
- Completion
- Dec 22, 2025 (Actual)
- Last update posted
- Sep 30, 2026
2024 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 10
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nat Res Inst Huntington Park | Huntington Park | California | 90255 | — |
| Valley Clinical Trials, Inc. | Northridge | California | 91325 | — |
| Southern California Dermatology | Santa Ana | California | 92701 | — |
| Encore Medical Research LLC | Hollywood | Florida | 33024 | — |
| Headlands Research Orlando | Orlando | Florida | 32819 | — |
| Encore Medical Research of Weston | Weston | Florida | 33331 | — |
| Alliance for Multispec Res | Newton | Kansas | 67114 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Arcturus HC PLC Troy Med Res | Troy | Michigan | 48098 | — |
| Southgate Medical Group, LLP | West Seneca | New York | 14224 | — |
| Summit Research Network Oregon Inc. | Portland | Oregon | 97210 | — |
| Holston Medical Group | Kingsport | Tennessee | 37660 | — |
| Amarillo Medical Specialists | Amarillo | Texas | 79124 | — |
| Elligo Clin Res Centre | Austin | Texas | 78704 | — |
| Headlands Research Brownsville | Brownsville | Texas | 78526 | — |
| Velocity Clinical Res-Dallas | Dallas | Texas | 75230 | — |
| Northeast Clinical Research of San Antonio | San Antonio | Texas | 78233 | — |
| Consano Clinical Research, LLC | Shavano Park | Texas | 78231 | — |
| Sugar Lakes Family Practice PA | Sugar Land | Texas | 77479 | — |
| Valley Diab. & Endo Comp Ctr | Weslaco | Texas | 78596 | — |
| TPMG Clinical Research | Newport News | Virginia | 23606 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06323174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06323174 live on ClinicalTrials.gov.